CA3087622A1 - Treatment of myopic progression - Google Patents

Treatment of myopic progression Download PDF

Info

Publication number
CA3087622A1
CA3087622A1 CA3087622A CA3087622A CA3087622A1 CA 3087622 A1 CA3087622 A1 CA 3087622A1 CA 3087622 A CA3087622 A CA 3087622A CA 3087622 A CA3087622 A CA 3087622A CA 3087622 A1 CA3087622 A1 CA 3087622A1
Authority
CA
Canada
Prior art keywords
copper
composition
containing agent
eye
ophthalmic
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3087622A
Other languages
English (en)
French (fr)
Inventor
Randon Michael BURR
Balamurali K. Ambati
Sarah A. MOLOKHIA
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Utah Research Foundation Inc
Original Assignee
University of Utah Research Foundation Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Utah Research Foundation Inc filed Critical University of Utah Research Foundation Inc
Publication of CA3087622A1 publication Critical patent/CA3087622A1/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/34—Copper; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/10—Ophthalmic agents for accommodation disorders, e.g. myopia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A61K9/0051—Ocular inserts or implants

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Plant Substances (AREA)
CA3087622A 2018-01-05 2019-01-07 Treatment of myopic progression Pending CA3087622A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862614230P 2018-01-05 2018-01-05
US62/614,230 2018-01-05
PCT/US2019/012501 WO2019136358A1 (en) 2018-01-05 2019-01-07 Treatment of myopic progression

Publications (1)

Publication Number Publication Date
CA3087622A1 true CA3087622A1 (en) 2019-07-11

Family

ID=67143996

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3087622A Pending CA3087622A1 (en) 2018-01-05 2019-01-07 Treatment of myopic progression

Country Status (8)

Country Link
US (2) US11524032B2 (https=)
EP (1) EP3735209A4 (https=)
JP (3) JP7324208B2 (https=)
KR (2) KR20250109788A (https=)
CN (1) CN112105320A (https=)
AU (2) AU2019205774B2 (https=)
CA (1) CA3087622A1 (https=)
WO (1) WO2019136358A1 (https=)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11065275B2 (en) * 2016-03-08 2021-07-20 University Of Utah Research Foundation Cross-linking agents and associated methods
KR20250109788A (ko) * 2018-01-05 2025-07-17 유니버시티 오브 유타 리서치 파운데이션 근시 진행의 치료
CA3146848A1 (en) * 2019-07-11 2021-01-14 University Of Utah Research Foundation Multi-agent ocular formulations and treatment methods
TW202245810A (zh) * 2021-02-01 2022-12-01 美商艾維娜傳送系統公司 散光之治療
TW202302121A (zh) * 2021-02-11 2023-01-16 猶他大學研究基金會 近視之治療
CN115282349A (zh) * 2022-07-05 2022-11-04 复旦大学附属眼耳鼻喉科医院 一种有利于改善孟加拉玫瑰红-绿光角膜胶原交联技术中cct降低的角膜交联试剂
CN115386105B (zh) * 2022-08-26 2024-03-22 昆明理工大学 多重酶活性纳米酶荧光水凝胶的制备方法及应用

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3416530A (en) 1966-03-02 1968-12-17 Richard A. Ness Eyeball medication dispensing tablet
DE68913995T2 (de) 1989-09-27 1994-08-25 Mo Ni Skij I Glaznych Boleznej Zusammensetzung zur behandlung progressiver myopie.
EP1159941A3 (en) * 1991-10-15 2003-09-17 Ista Pharmaceuticals, Inc. Formulations for use in enzyme-orthokeratology
CN1047523C (zh) * 1993-11-23 1999-12-22 华中理工大学 一种防治近视的滴眼液
AU7488898A (en) 1997-05-16 1998-12-08 Corrective Vision, Inc. Improved contact lens
BR9908692A (pt) * 1998-03-09 2001-12-04 Ista Pharmaceuticals Inc Uso de agentes de enrijecimento corneal emortocerotologia enzimática
US6231889B1 (en) * 1998-09-21 2001-05-15 Chronorx, Llc Unit dosage forms for the treatment of herpes simplex
CA2443244A1 (en) * 2001-04-13 2002-10-24 Incyte Genomics, Inc. Enzymes
IL158904A0 (en) 2001-05-25 2004-05-12 Valley Forge Pharmaceuticals Pirenzepine ophthalmic gel
NZ540885A (en) * 2002-12-20 2009-02-28 Chakshu Res Inc Ophthalmic formulation for the prevention and treatment of ocular conditions
CN1518981A (zh) * 2003-07-23 2004-08-11 复旦大学附属眼耳鼻喉科医院 一种治疗近视的外用滴眼制剂
MXPA03011987A (es) * 2003-12-19 2005-06-23 Osio Sancho Alberto Metodo para el tratamiento de la presbicia induciendo cambios en el poder y fisiologia corneal.
WO2006055526A2 (en) 2004-11-16 2006-05-26 Nu-Tein Co., Inc. Compositions useful to treat ocular neovascular diseases and macular degeneration
US20060276777A1 (en) * 2005-04-08 2006-12-07 Coroneo Minas T Corneal shaping
US20080014278A1 (en) 2006-06-30 2008-01-17 Nucryst Pharmaceuticals Metal-containing formulations and methods of use
WO2012161655A1 (en) 2011-05-23 2012-11-29 Singapore Health Services Pte Ltd Composition and/or method for reducing and/or preventing myopia progression comprising atropine
US20140343480A1 (en) * 2013-05-19 2014-11-20 Avedro, Inc. Systems, methods, and compositions for cross-linking
RU2635185C2 (ru) * 2013-12-17 2017-11-09 Иван Дмитриевич Захаров Фармацевтический препарат для профилактики и лечения прогрессирующей близорукости
WO2015155117A1 (en) * 2014-04-09 2015-10-15 Universität Leipzig A device for a medical treatment of a sclera
US9421199B2 (en) 2014-06-24 2016-08-23 Sydnexis, Inc. Ophthalmic composition
CN107530324A (zh) * 2015-04-09 2018-01-02 雷伯瑞特里巴达西公司 用于眼科用途的吡咯烷酮羧酸（pca）
US10010502B2 (en) 2015-05-19 2018-07-03 Amorphex Therapeutics Llc Device that delivers a sustained low-dose of a myopia-suppressing drug, while preserving pupillary function and accommodation
US11065275B2 (en) 2016-03-08 2021-07-20 University Of Utah Research Foundation Cross-linking agents and associated methods
AU2018371787A1 (en) 2017-11-21 2020-11-05 Sydnexis, Inc. Ophthalmic composition and delivery device thereof
KR20250109788A (ko) * 2018-01-05 2025-07-17 유니버시티 오브 유타 리서치 파운데이션 근시 진행의 치료
CA3146848A1 (en) * 2019-07-11 2021-01-14 University Of Utah Research Foundation Multi-agent ocular formulations and treatment methods
TW202245810A (zh) * 2021-02-01 2022-12-01 美商艾維娜傳送系統公司 散光之治療
TW202302121A (zh) * 2021-02-11 2023-01-16 猶他大學研究基金會 近視之治療

Also Published As

Publication number Publication date
JP7655988B2 (ja) 2025-04-02
EP3735209A1 (en) 2020-11-11
AU2019205774B2 (en) 2025-01-02
US12544400B2 (en) 2026-02-10
AU2024278182A1 (en) 2025-01-02
KR20200118426A (ko) 2020-10-15
WO2019136358A1 (en) 2019-07-11
US20230256012A1 (en) 2023-08-17
KR102831250B1 (ko) 2025-07-08
US11524032B2 (en) 2022-12-13
JP2025111434A (ja) 2025-07-30
AU2019205774A1 (en) 2020-08-06
US20210060059A1 (en) 2021-03-04
CN112105320A (zh) 2020-12-18
JP2023153905A (ja) 2023-10-18
JP2021509902A (ja) 2021-04-08
KR20250109788A (ko) 2025-07-17
JP7324208B2 (ja) 2023-08-09
EP3735209A4 (en) 2021-09-08

Similar Documents

Publication Publication Date Title
US12544400B2 (en) Treatment of myopic progression
AU2023202236B2 (en) Cross-linking agents and associated methods
AU2026201640A1 (en) Multi-agent ocular formulations and treatment methods
KR20240021734A (ko) 근시의 치료
HK40107891A (en) Cross-linking agents and associated methods

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20220927

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT RECEIVED - RESPONSE TO EXAMINER'S REQUISITION

Effective date: 20240802

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 6TH ANNIV.) - STANDARD

Year of fee payment: 6

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20250103

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT

Effective date: 20250103

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20250103

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20250120

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT DETERMINED COMPLIANT

Effective date: 20250225

P13 Application amended

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P13-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION AMENDED

Effective date: 20250225

D15 Examination report completed

Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D15-D126 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: EXAMINER'S REPORT

Effective date: 20250722

D00 Search and/or examination requested or commenced

Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D00-D120 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: VOLUNTARY SUBMISSION OF PRIOR ART RECEIVED

Effective date: 20251124

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT RECEIVED - RESPONSE TO EXAMINER'S REQUISITION

Effective date: 20251124

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT DETERMINED COMPLIANT

Effective date: 20260108

P13 Application amended

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P13-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION AMENDED

Effective date: 20260108

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20260108

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 7TH ANNIV.) - STANDARD

Year of fee payment: 7

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20260109

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20260109

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20260225

D00 Search and/or examination requested or commenced

Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D00-D123 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: PRIOR ART DISCLOSURE DETERMINED COMPLIANT

Effective date: 20260309

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20260309

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20260309